Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancer

Kesharwani, Prashant; Banerjee, Sanjeev; Padhyé, Subhash; Sarkar, Fazlul H.; Iyer, Arun K.

doi:10.1016/j.colsurfb.2015.05.007

Cited by 92 publications

(78 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observed results may be attributed to overexpression of comparatively more CD44 receptors in MiaPaCa-2 cells, which allow more amount of CDF delivered by the HA conjugated formulation (HA-PAMAM-CDF) within the cells and displayed better cell killing. Our results are in agreement with reported literature[5,26].…”

supporting

confidence: 96%

“…Drug release from known weight of CDF loaded plain PAMAM, and HA-PAMAM dendrimers were determined in acidic (pH 4.0) and physiological buffer (PBS, pH 7.4) using dialysis membrane diffusion technique [5,28]. Known amount of CDF loaded dendrimer formulations were separately placed inside the dialysis tubing (3.5 KDa, Sigma, USA), hermetically sealed and suspended immediately in 50 ml of released media under sink conditions.…”

Section: In Vitro Release Studiesmentioning

confidence: 99%

“…These reports clearly suggest the potential for CDF as a therapeutic agent for treatment of pancreatic cancer including CSLCs. However, poor aqueous solubility of CDF has made its systemic administration problematic [5]. The present study was aimed at developing a nano-formulation of HA-PAMAM engineered for CD44 mediated targeted delivery of CDF, with the aim to treat human pancreatic cancer including pancreatic CSLCs (Scheme 1).…”

Section: Introductionmentioning

confidence: 99%

“…Surmounting the many challenges of identifying a successful targeted drug delivery strategy requires an understanding of events involving transport of drug or drug carrier to a target site after administration as well as issues relevant for specific target diseases and the body's response toward a drug delivery system [4]. In this context, polymeric nanocarriers such as micelles, liposomes, nanoparticles, and dendrimers could be valuable options [5,6].…”

Section: Introductionmentioning

confidence: 99%

“…We have developed a highly promising derivative of curcumin known as 3,4-difluorobenzylidene curcumin (CDF) that not only showed 16-fold increase in half-life and superior anticancer activity but also showed better pancreas accumulation than curcumin [5,20,21]. More prominently, CDF could inhibit the growth of cancer stem like cells (CSLCs) are (including but not limited to) through deregulation of multiple miRNAs, induction of phosphatase and tensin homolog (PTEN), and attenuation of histone methyltransferase EZH2 [22][23][24].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells

Kesharwani

Xie

Banerjee

et al. 2015

Colloids and Surfaces B: Biointerfaces

Self Cite

181

View full text Add to dashboard Cite

supporting

confidence: 96%

Section: In Vitro Release Studiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells

Kesharwani

Xie

Banerjee

et al. 2015

Colloids and Surfaces B: Biointerfaces

Self Cite

181

View full text Add to dashboard Cite

Curcumin – Bioavailability Enhancement by Prodrug Approach and Novel Formulations

Chelimela,

Alavala,

Satla

2024

Chemistry & Biodiversity

View full text Add to dashboard Cite

Curcumin, is a diverse natural pharmacological agent involved in various signal transduction mechanisms. Therapeutically, this potent molecule facing different challenges and issues related to low bioavailability due to its poor aqueous solubility, less permeability, faster elimination and clearance. Experts in synthetic chemistry and pharmaceuticals are continuously sparing their efforts to overcome these pharmacokinetic challenges by using different structural modification strategies and developing novel drug delivery systems. In this mini‐review article, we are focusing on different possible routes like conjugation with biomolecules, natural polymers, synthetic polymers, natural products, metal conjugates and co‐administration with natural metabolic inhibitors and preparation of modified formulations such as micelles, microemulsions, liposomes, complexes with phospholipids, micro and nanoemulsions, solid lipid nanoparticles, nano lipid carriers, biopolymer nanoparticles and microgels to improve the pharmacokinetic properties of the curcumin without altering its pharmacodynamics activity. Hope this review helps to understand the problems associated with curcumin and different strategies to improve the pharmacokinetic profile of the curcumin.

show abstract

Therapeutic effect of curcumin in gastrointestinal cancers: A comprehensive review

Morshedi

Borran

Ebrahimi

et al. 2021

Phytotherapy Research

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers with a high global prevalence are a leading cause of morbidity and mortality. Accordingly, there is a great need to develop efficient therapeutic approaches. Curcumin, a naturally occurring agent, is a promising compound with documented safety and anticancer activities. Recent studies have demonstrated the activity of curcumin in the prevention and treatment of different cancers. According to systematic studies on curcumin use in various diseases, it can be particularly effective in GI cancers because of its high bioavailability in the gastrointestinal tract. Nevertheless, the clinical applications of curcumin are largely limited because of its low solubility and low chemical stability in water. These limitations may be addressed by the use of relevant analogues or novel delivery systems. Herein, we summarize the pharmacological effects of curcumin against GI cancers. Moreover, we highlight the application of curcumin's analogues and novel delivery systems in the treatment of GI cancers.

show abstract

Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancer

Cited by 92 publications

References 45 publications

Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells

Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells

Curcumin – Bioavailability Enhancement by Prodrug Approach and Novel Formulations

Therapeutic effect of curcumin in gastrointestinal cancers: A comprehensive review

Contact Info

Product

Resources

About